Document Detail


Development of chronic lung disease in preterm infants treated with surfactant.
MedLine Citation:
PMID:  12225547     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chronic lung disease (CLD) is generally known to develop among preterm infants who have severe respiratory distress syndrome (RDS) at birth. Many clinical trials have established the efficacy of surfactant replacement therapy to treat RDS at birth with differing doses. In this study, the preterm infants diagnosed to have RDS at birth and treated with one or two doses of surfactant, depending on the severity of the RDS, were studied to evaluate the effect of surfactant on the later development of CLD. METHODS: A retrospective examination of case records of preterm infants who were born at < or = 28 weeks gestation period were studied. The subjects received a natural surfactant product (survanta) between September 1994 and April 1996 at the Monash Medical Center, Australia. RESULTS: Despite less severe initial lung disease, the subsequent respiratory outcome of infants who received one dose of surfactant, showed a trend towards being poorer compared to those who were diagnosed as having severe RDS at birth and received two doses of surfactant. At the corrected gestational age of 36 weeks, 54% of those infants began with mild RDS required oxygen, while only 44% of those who started with a severe RDS required supplemental O2. CONCLUSION: This study reports the infants with severe RDS at birth had responded slightly better or equally, compared to those with mild RDS, in terms of later development of CLD under surfactant treatment proportional to the severity.
Authors:
Majeda S Hammoud; Lukman Thalib
Related Documents :
14733787 - Prophylaxis of neonatal respiratory distress syndrome by intra-amniotic administration ...
7808837 - Dexamethasone treatment of infants at risk for chronic lung disease: surfactant compone...
1030167 - Prevention of respiratory distress syndrome by antenatal maternal steroid treatment.
15201857 - Immediate changes in lung compliance following natural surfactant administration in pre...
8868517 - Apc resistance in neonates and infants: adjustment of the aptt-based method.
17937687 - Breastfeeding promotion in neonatal intensive care unit: impact of a new program toward...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatrics international : official journal of the Japan Pediatric Society     Volume:  44     ISSN:  1328-8067     ISO Abbreviation:  Pediatr Int     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-09-12     Completed Date:  2002-11-20     Revised Date:  2008-05-21    
Medline Journal Info:
Nlm Unique ID:  100886002     Medline TA:  Pediatr Int     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  493-9     Citation Subset:  IM    
Affiliation:
Monash Medical Center, Monash University, Victoria, Australia. m.hammoud@hsc.kuniv.edu.kw
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Products*
Chronic Disease
Female
Humans
Infant, Newborn
Lung Diseases / etiology*
Male
Pulmonary Surfactants / therapeutic use*
Respiratory Distress Syndrome, Newborn / drug therapy*
Retrospective Studies
Chemical
Reg. No./Substance:
0/Biological Products; 0/Pulmonary Surfactants; 108778-82-1/beractant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Follow-up study of auditory brainstem responses in infants with high unbound bilirubin levels treate...
Next Document:  Different expression of surfactant protein B mature peptide and proprotein at 21 weeks' gestation in...